fda drug shortage list semaglutide US judge upholds FDA's removal of Ozempic, Wegovy from FDA: Novo Nordisk's Ozempic and

The data presented here comes from published clinical trials and company press releases

MASLD/Fatty Liver Disease Given the remarkable liver fat clearance data, individuals with diagnosed metabolic liver disease may see outsized benefits from retatrutide compared to other options.

What the FDA Requires in the BLA Efficacy Data: TRIUMPH-4: 28.7% weight loss Complete TRIUMPH-1: 28.3% weight loss Complete TRIUMPH-2: 20.8% weight loss (obesity + diabetes) Complete TRIUMPH-3: 22.6% weight loss (obesity + cardiovascular disease) Complete, MACE data not statistically significant Safety Data: Side effect profile across all four populations Short-term and medium-term adverse events, including the dysesthesia signal (up to 20.9% at 12mg) Drug interactions, especially with diabetes medications Manufacturing Data: Scale-up capability for millions of doses per month Quality control and stability data Cold chain distribution logistics Realistic Approval Scenarios With the BLA filing point now expected (Q1 2027), the remaining uncertainty is largely in the FDA review itself not in whether or when Lilly files

Multimolecular assemblies on high surface area metal oxides and their role in interfacial energy and electron transfer

Clinical Update 4/26/2024 Alpha-Lipoic Acid for Nerve Pain

Were Here to Help